However, owing to the inefficacy of soluble Fas L in apoptosis induction 34 and the systematic toxicity of TNFα 35, potent TRAIL without dose-limited toxicity must be the best choice for combination with PDT in cancer therapy. The gene discussed is TNFSF10; the disease is cancer.